# Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)

> **NCT00592553** · PHASE2 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 174 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy
- Becker Muscular Dystrophy

## Interventions

- **DRUG:** Ataluren
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00592553
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-29
- **Primary completion:** 2009-12-31
- **Final completion:** 2009-12-31
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2020-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00592553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00592553, "Phase 2B Study of PTC124 (Ataluren) in Duchenne/Becker Muscular Dystrophy (DMD/BMD)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00592553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*